Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORBIT: Linsitinib in Moderate to Severe Active Thyroid Eye Disease
NCT07753603Phase 3Recruiting
- Sponsor
- Sling Therapeutics, Inc.
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 3 trial of linsitinib in thyroid eye disease (TED), sponsored by Sling Therapeutics, Inc.. Started Aug 2026; status: recruiting.
02
Drugs
linsitinib
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07753603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753603.